Compare BCO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCO | LEGN |
|---|---|---|
| Founded | 1859 | 2014 |
| Country | United States | United States |
| Employees | 125 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2010 | 2020 |
| Metric | BCO | LEGN |
|---|---|---|
| Price | $111.16 | $19.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $146.33 | $45.62 |
| AVG Volume (30 Days) | 374.3K | ★ 1.8M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 29.20 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $3,562,300,000.00 | N/A |
| Revenue This Year | $6.24 | $39.73 |
| Revenue Next Year | $3.95 | $23.42 |
| P/E Ratio | $60.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.05 | $16.24 |
| 52 Week High | $136.37 | $37.50 |
| Indicator | BCO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 51.45 |
| Support Level | $108.20 | $17.08 |
| Resistance Level | $112.70 | $19.92 |
| Average True Range (ATR) | 2.81 | 0.86 |
| MACD | 1.22 | 0.11 |
| Stochastic Oscillator | 77.75 | 68.43 |
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provide BGS services and BGS activity in Latin American countries. It derives maximum revenue from the North America segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.